ViewRay (VRAY) Board of Directors has retained Goldman Sachs and Co. LLC as a financial advisor to undertake an evaluation of strategic alternatives, including a

SiriusPoint Ltd (SPNT) has acknowledged an indication of interest from Third Point LLC and certain of its affiliates, disclosed in a Schedule 13D/A filing, to explore

Aeglea BioTherapeutics (AGLE) a clinical-stage biotechnology company announced that it is exploring strategic alternatives with the goal of maximizing shareholder value.

Activist Investor Trillium Capital pushes Getty Images Holding (GETY) the stock-photo company to evaluate strategic options including a sale. Update(s): April 24, 2023: Reuters reported

According to Bloomberg, Mobile game developer Playtika Holding Corp. (PLTK) has attracted renewed takeover interest from private equity buyers Previously on February 28, 2022, Playtika

According to WSJ, Exxon Mobil Corp. (XOM) has held preliminary talks with Pioneer Natural Resources Co. (PXD) about a possible acquisition. Update(s): October 5, 2023:

Liminal BioSciences (LMNL) the Board of Directors of the company received a non-binding proposal from Structured Alpha LP outlining a potential transaction to acquire all

Teck Resources Limited (TECK) announced that the Board of Directors of Teck has received and unanimously rejected an unsolicited and opportunistic acquisition proposal from Glencore

According to Bloomberg, Apellis Pharmaceuticals (APLS) a biotech firm focused on rare diseases and ophthalmology, is drawing takeover interest from larger drugmakers.

GreenLight Biosciences (GRNA) confirmed that it has received a non-binding indication of interest from Fall Line Endurance Fund, L.P. to acquire all of the outstanding

According to Bloomberg, BridgeBio Pharma (BBIO) which develops treatments for genetic diseases, is attracting takeover interest from bigger drug companies, according to people familiar with

Echo Lake Capital offers to acquire Quince Therapeutics (QNCX) for $1.60 per share in cash. Update(s): April 11, 2023: Quince Therapeutics, Inc. (QNCX) announced that